Clinical solution for accurate detection of breast cancer

Breast cancer is often called the "pink killer" and its incidence ranks first among female malignant tumors. In China, the incidence of breast cancer is increasing year by year, with more than 300,000 women diagnosed with breast cancer each year. With the improvement of medical standards, breast cancer has become one of the most effective solid tumors.

Assessing prognosis

HER2-positive breast cancer generally has a poor prognosis

Whether PIK3CA is mutated affects the classification and diagnosis of breast cancer

Classification and diagnosis

Whether PIK3CA is mutated affects the classification and diagnosis of breast cancer

Targeted therapy

NTRK is an important target for anti-tumor drugs

Monitoring treatment effectiveness

By detecting changes in HER2 expression levels, the effect of treatment can be evaluated and the treatment plan can be adjusted in time to achieve better clinical results.

Predicting Response

121006024 HER2 Gene Amplification Digital PCR Detection Kit

121008024 HER2 Gene Amplification/Exon 20 Insertion Mutation Digital PCR Detection Kit

121009024 PIK3CA Gene Mutations Digital PCR Detection Kit

121013024 NTRK Gene Fusion Digital PCR Detection Kit

Equipment and Supplies

N10001.3  Naica® digital PCR system-3 color                                      

N10001.3  Naica® digital PCR system-3 color                                      

N30027.0  Nio™+Ultimate dPCR

C16011     Ruby Chips                                                                                         

C14012    Sapphire Chips

Sample collection

Nucleic acid extraction, PCR system configuration and sample addition

Droplet generation and expansion

Droplet generation and expansion